Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
American Journal of Therapeutics|January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentMichael D Mayer, Reza Khosravan, Laurent Vernillet, et al.
Journal of Clinical Pharmacology|January 7, 2006
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseReza Khosravan, Brian A Grabowski, Michael D Mayer, et al.
Journal of Religion and Health|February 8, 2012
Emerging worldviews: the supplicate order-invocation of the sacredPatricia MacDonald Brown
Current Medical Research and Opinion|March 16, 2007
Metabolic syndrome-related conditions among people with and without gout: prevalence and resource useSuzanne Novak, Arthur K Melkonian, Pankaj A Patel, et al.
The Journal of Rheumatology|December 7, 2005
Tophaceous gout: quantitative evaluation by direct physical measurementH Ralph Schumacher, Michael A Becker, William A Palo, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|September 23, 2021
Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 StudyJarrod P Holmes, Julio A Peguero, R Campbell Garland, et al.
Arthritis and Rheumatism|November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trialH Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 25, 2007
The impact of gout on work absence and productivityNathan L Kleinman, Richard A Brook, Pankaj A Patel, et al.
Current Medical Research and Opinion|July 13, 2006
The economic burden of gout on an employed populationRichard A Brook, Nathan L Kleinman, Pankaj A Patel, et al.
Arthritis and Rheumatism|March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
Pageof 4